FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 351:1690-1691 October 14, 2004 Number 16 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Hurwitz, H. PubMed Citation

To the Editor: The randomized study reported by Hurwitz and associates (June 3 issue)¹ did not allow the crossover of patients with disease progression in the group that received placebo to treatment with bevacizumab. Although this strategy can enhance the probability of detecting a difference in survival between the study groups, it is inherently unethical to disallow access to the study drug on progression of disease in patients in the placebo group. The lack of crossover also fails to simulate the commonplace occurrence of crossover in the practice of medical oncology.

Guru Sonpavde, M.D.
Baylor College of Medicine
Houston, TX . . . [Full Text of this Article]

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.